|Day Low/High||38.88 / 42.65|
|52 Wk Low/High||19.91 / 63.60|
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component EXACT Sciences Corp. was identified as having a larger market cap than the smaller end of the S&P 500, for example Tripadvisor Inc , according to The Online Investor.
The stock still looks vulnerable to further declines from a technical perspective.
Kevin Conroy, chairman and CEO of Exact Sciences, tells Jim Cramer about his company's expansion plans for cancer screening tests.
From global growth and bonds to index funds, Jim Cramer explains why stocks keep going up, giving the Dow and Nasdaq their best start to the new year since 2006.
- Preliminary 2017 revenue between $265.5 million and $266.5 million, a year-over-year increase of 168 percent
World-class lab and office space to support demand for Cologuard
Jim Cramer is bullish on Exact Sciences, Cognizant Technology, MetLife, JPMorgan Chase and more.
Sentiment is critical to the next market move, says Jim Cramer. A little negativity is great news for the bulls.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in EXACT Sciences Corp. , where a total volume of 9,758 contracts has been traded thus far today, a contract volume which is representative of approximately 975,800 underlying shares (given that every 1 contract represents 100 underlying shares).
The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 5,295,292 share decrease in total short interest for EXACT Sciences Corp. , to 10,994,802, a decrease of 32.51% since 09/15/2017.
Analysts, consultants and Shopify users came to the company's defense when TheStreet reached out to them.
The most recent short interest data has been released for the 09/15/2017 settlement date, which shows a 2,075,458 share decrease in total short interest for EXACT Sciences Corp. , to 16,290,094, a decrease of 11.30% since 08/31/2017.
The most recent short interest data has been released for the 07/31/2017 settlement date, which shows a 2,304,856 share decrease in total short interest for EXACT Sciences Corp. , to 18,237,019, a decrease of 11.22% since 07/14/2017.
Venture Capital firm Benchmark reiterated its 'Buy' rating on the stock and $50 price target.
The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 2,463,634 share decrease in total short interest for EXACT Sciences Corp. , to 22,030,168, a decrease of 10.06% since 05/31/2017.
Golfer launches multi-year, Cologuard®-branded campaign
The secondary offering, to be underwritten by Jefferies, Bank of America/Merrill Lynch and Robert W. Baird, would offer 7 million shares.
Plus more from the biotechnology world on Wednesday, June 7.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.